The primary purpose of this study is to assess incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept.
Study Type
OBSERVATIONAL
Enrollment
92,635
Hospitalized infection
Time frame: Every 6 months throughout the study
Malignancy (total, lymphoma, lung cancer, breast cancer, colorectal cancer, prostate cancer)
Time frame: Every 6 months throughout the study
Total mortality
Time frame: Every 6 months throughout the study
Autoimmune disorders (lupus, psoriasis, multiple sclerosis)
Time frame: Every 6 months throughout the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.